No hantavirus vaccine candidate has advanced to Phase 3 efficacy trials as of mid-2026, underpinning the market-implied 94.5% probability against any full FDA approval by year-end. Early-stage DNA and mRNA platforms targeting orthohantavirus Gn-Gc glycoproteins have shown neutralizing antibodies in preclinical models and limited Phase 1 safety data, yet low disease incidence, rodent-borne transmission, and the absence of large-scale human efficacy testing constrain rapid progress. A May 2026 cruise-ship outbreak heightened surveillance and modest funding interest but has not altered regulatory timelines, which typically require multiple years beyond Phase 2. Unexpected emergency use authorization or accelerated review remains possible but lacks precedent for this pathogen given current trial trajectories.